Bristol-Myers Squibb Company cash flow to debt ratio of 30.03% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Bristol-Myers Squibb Company's free cash flow has decreased 7.87% from $13.94B last year to $12.85B, signaling decreasing performance

Bristol-Myers Squibb Company's debt to equity ratio is 1.93, which means that the company's assets are unhealthy financed, signaling financial risk.

Bristol-Myers Squibb Company's debt has decreased relative to shareholder equity from 3.13 last year to 1.93 today, signaling strengthened financials

Bristol-Myers Squibb Company has a net debt to EBITDA ratio of 2.39x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Bristol-Myers Squibb Company's interest coverage ratio of 8.04 indicates that earnings with good margin can cover interest payments on company debt

Bristol-Myers Squibb Company's profit margin was -18.53% last year and is 18.87% this year, signaling increasing performance

Bristol-Myers Squibb Company's short-term assets of $29.39B exceed its short-term liabilities of $23.42B

Bristol-Myers Squibb Company's return on assets of 10.59% is higher than the 5.00% threshold, indicating efficient asset utilization

Bristol-Myers Squibb Company's return on equity of 46.75%, is higher than 15.00%, indicating good performance

Bristol-Myers Squibb Company's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Bristol-Myers Squibb Company had positive net income in 4 out of 5 years, indicating stable and consistent earnings

Bristol-Myers Squibb Company has positive free cash flow, indicating the company generates cash after capital expenditures

Bristol-Myers Squibb Company has a free cash flow yield of 9.84%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Bristol-Myers Squibb Company's yearly earnings has increased 178.83% since last year from $-8.95B to $7.05B, signaling increasing performance

Bristol-Myers Squibb Company's yearly revenue has decreased 0.22% since last year from $48.30B to $48.19B, signaling decreasing performance

ROIC 15.47% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Bristol-Myers Squibb Company's 3-year revenue CAGR of 1.45% is positive, indicating growing revenue over the past 3 years

Bristol-Myers Squibb Company had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Bristol-Myers Squibb Company had positive ROE in 4 out of 5 years, indicating consistent and reliable returns on equity

Bristol-Myers Squibb Company is overvalued relative to its fair value price of 53.66 based on Base Cash Flow Valuation (DCF) model

Bristol-Myers Squibb Company has an earnings yield of 7.12%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Bristol-Myers Squibb Company is overvalued relative to its fair value price of 34.37 based on Base EBITDA Valuation model

Bristol-Myers Squibb Company has an EV/EBITDA ratio of 10.96x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Bristol-Myers Squibb Company is overvalued relative to its fair value price of 57.07 based on Base Earnings Fair Value model

Bristol-Myers Squibb Company had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Bristol-Myers Squibb Company has a price-to-book ratio of 5.84x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Bristol-Myers Squibb Company has a price-to-sales ratio of 2.65x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue